Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.

Become a Member

Upcoming SFPM Events

AACR ANNUAL MEETING 2024

FPM SESSIONS
AT05 - Novel Experimental Models for Functional Precision Genomics (Alice Soragni, Chairperson)
ED33 - What is the Stat of the Art in Functional Precision Medicine? (Anthony Letai, Diana Azzam, Berend Snijder)
DC01 - Navigating Laboratory Developed Tests in Oncology: Emerging Needs and Opportunities (Anthony Letai, Keith Ligon)
ADT03 - Ex Vivo Functional Diagnostics for Cancer Precision Medicine (Jeff Tyner, Caroline Heckman, Shannon Mumenthaler)
AT05 - Novel Experimental Models for Functional Precision Genomics (Alice Soragni, Anne Rios, Matthew Garnett)

EHA-SFPM PRECISION MEDICINE MEETING

EHA-SFPM Precision Medicine Meeting
The SFPM is excited to announce that in partnership with European Hematology Association, we will be organizing a Precision Medicine Meeting; Bridging between functional and genomic precision medicine, to be held September 25-27, 2024, Copenhagen, Denmark. We will continue to post updates as they become available.

Call for Board Member Nominations

Do you want to help shape the future of the SFPM?  Self-nominate for a board position today and lend your experience and input!

Open positions for this election cycle include

Positions will be filled by vote of the Professional or Associate members in good standing. You must be a Professional or Associate member to view the form and apply.

Membership

The SFPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits

Applications for membership may be submitted at any time during the year. We look forward to having you onboard!

Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series should not be missed for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Next Seminar

Wednesday, March 13, 2024

@

12:00 PM EDT

UPDATED TIME - NOW 12 PM EASTERN TIME ZONE

Meeting URL: www.zoom.us
Meeting ID: 828 5622 5783
Passcode: 027718

Ina Oehme, PhD
Ina Oehme, PhD
Hopp Children’s Cancer Center Heidelberg and German Cancer Research Center
Drug sensitivity profiling of 3D tumor tissue cultures in the precision oncology programs MASTER & INFORM

Next Seminar

Wednesday, March 13, 2024

@

12:00 PM EDT

UPDATED TIME - NOW 12 PM EASTERN TIME ZONE

Meeting URL: www.zoom.us
Meeting ID: 828 5622 5783
Passcode: 027718

Claudia R. Ball, PhD
Claudia R. Ball, PhD
National Center for Tumor Diseases Dresden and German Cancer Research Center
Drug sensitivity profiling of 3D tumor tissue cultures in the precision oncology programs MASTER & INFORM

Recent News

Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked. Check out our news archive for all past stories and posts.

Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies
January 23, 2024

Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies

Cancer patients with advanced-stage disease have poor prognosis, typically having limited options for efficacious treatment, and genomics-based therapy guidance continues to benefit only a fraction of patients. Next-generation ex vivo approaches, such as cell mass-based response testing (MRT), offer an alternative precision medicine approach for a broader population of patients with cancer, but validation of clinical feasibility and potential impact remain necessary.

Read MORE
Cancer Patient Lab Meeting #11 - "Functional Precision Testing"
January 15, 2024

Cancer Patient Lab Meeting #11 - "Functional Precision Testing"

Tony Letai, MD, PhD, Professor at Dana Farber Cancer Institute, and President, Society for Functional Precision Medicine, led a discussion on "Functional Precision Medicine for Advanced Cancer". As we look at novel, personalized therapies, how can we have confidence that they will work?

Read MORE
Cancer Patient Lab Meeting #18 - "Functional Drug Testing and AI/ML for Treatment Decisions"
January 15, 2024

Cancer Patient Lab Meeting #18 - "Functional Drug Testing and AI/ML for Treatment Decisions"

Noah Berlow, PhD, CTO, First Ascent Biomedical, and Diana Azzam, PhD, Assistant Professor at Florida International University, led a discussion on their approach to functional drug testing and using AI/ML to guide complex treatment decisions for advanced cancer patients.

Read MORE
Cancer Patient Lab Meeting #13 - "Organoids Guide Treatment Decisions"
January 15, 2024

Cancer Patient Lab Meeting #13 - "Organoids Guide Treatment Decisions"

Payel Chatterjee, Chief Scientist, SEngine Precision Medicine, led a discussion on the role of organoids in guiding cancer treatment decisions. The value proposition of “functional testing” (applying 100 or more drugs to fresh tumor tissue and seeing how the cancer responds) is that this very direct approach can identify unexpected drugs to try, and extraordinary results, for some patients.

Read MORE
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
October 16, 2023

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

Ex vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641). We conclude that ex vivo drug response profiling is clinically feasible and has the potential to predict chemotherapy response in individuals with hematologic malignancies beyond clinically established genetic markers.

Read MORE
PMNET Meeting in Riga, Latvia
September 11, 2023

PMNET Meeting in Riga, Latvia

Many SFPM stalwarts will be speaking at the PMNET meeting in Riga, Latvia October 12-13. Please visit pmnetforum.com to register for in-person or virtual access to this exciting meeting!

Read MORE

Support the SFPM

The SFPM is growing, and we need financial support. While we collect annual individual membership dues, these only fund a fraction of our needs. To plan for the future, the SFPM must secure a stable financial basis from which to plan. Even though the Board is made up of unpaid volunteers, we nonetheless have significant costs to defray, particularly with respect to annual meetings and administrative support.

Contributions from all tiers will be recognized by name on the SFPM website, however, contributions at the Precision tier will receive preferred logo placement and recognition on the SFPM website, logo and name recognition at each monthly seminar, and institution name and logo prominently displayed at our annual meeting and on meeting marketing materials. Precision tier supporters will also receive ten (10) complimentary memberships to be distributed amongst their institutions. Functional tier supporters will receive name and logo recognition during at least six of our monthly seminars as well as name and logo recognition on our website. Functional tier supporters will also receive five (5) complimentary memberships to be distributed amongst their institutions. Advocate tier supporters will receive name and logo recognition on our website and one (1) complimentary membership. We hope you agree with us that “the future is functional”, and that the SFPM is getting us there faster.

Thank You Sponsors